Timothy Axtelle BS

Vice President, Research & Development

In more than 16 years of biopharmaceutical industry experience in the US, Tim has led teams in all phases of drug development from discovery through clinical development, licensing and post-marketing. In his last position as Director, Therapeutic Development at ICOS Corporation, he was responsible for developing drugs for severe sepsis, infectious disease, autoimmune disease and erectile dysfunction. Tim Axtelle’s previous experience includes time as a research scientist at Immunetech Pharmaceuticals (San Diego CA) and at the Fred Hutchinson Cancer Research Center (Seattle WA). Tim leads the team developing Implicit’s clinical-stage drug oglufanide in various infectious disease indications relevant to commercial, biodefense and global health markets.